VENUS REMEDIES
|
VENUS REMEDIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 21.31 | 19.87 | 30.47 | 50.04 | -8.10 |
| CEPS(Rs) | 41.10 | 44.04 | 55.55 | 78.63 | 17.84 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 364.74 | 344.38 | 329.50 | 313.18 | 262.01 |
| Tax Rate(%) | 36.18 | 29.96 | -11.85 | -27.21 | -24.44 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 9.91 | 10.81 | 10.35 | 9.81 | 12.03 |
| EBIT Margin(%) | 7.44 | 6.85 | 6.15 | 11.23 | 1.56 |
| Pre Tax Margin(%) | 7.42 | 6.83 | 6.07 | 8.86 | -2.37 |
| PAT Margin (%) | 4.74 | 4.78 | 6.79 | 11.27 | -2.95 |
| Cash Profit Margin (%) | 9.13 | 10.60 | 12.37 | 17.70 | 6.49 |
| Performance Ratios | |||||
| ROA(%) | 4.64 | 4.50 | 7.18 | 10.30 | -1.45 |
| ROE(%) | 6.01 | 5.90 | 9.85 | 17.40 | -3.05 |
| ROCE(%) | 8.67 | 7.72 | 7.89 | 12.37 | 0.90 |
| Asset Turnover(x) | 0.98 | 0.94 | 1.06 | 0.91 | 0.49 |
| Sales/Fixed Asset(x) | 0.98 | 0.91 | 0.98 | 0.88 | 0.51 |
| Working Capital/Sales(x) | 2.15 | 2.31 | 3.24 | 4.01 | 4.89 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.02 | 1.09 | 1.02 | 1.13 | 1.96 |
| Receivable days | 47.69 | 37.87 | 21.48 | 20.89 | 36.97 |
| Inventory Days | 73.32 | 80.68 | 74.69 | 86.94 | 152.66 |
| Payable days | 48.87 | 55.69 | 57.31 | 57.86 | 76.11 |
| Valuation Parameters | |||||
| PER(x) | 15.31 | 8.15 | 8.82 | 5.49 | - |
| PCE(x) | 7.94 | 3.68 | 4.84 | 3.49 | 1.26 |
| Price/Book(x) | 0.89 | 0.47 | 0.82 | 0.88 | 0.09 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.68 | 0.37 | 0.59 | 0.65 | 0.73 |
| EV/Core EBITDA(x) | 5.75 | 2.90 | 5.00 | 4.89 | 5.34 |
| EV/EBIT(x) | 9.15 | 5.37 | 9.54 | 5.83 | 46.42 |
| EV/CE(x) | 0.77 | 0.41 | 0.61 | 0.65 | 0.38 |
| M Cap / Sales | 0.73 | 0.39 | 0.60 | 0.62 | 0.08 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 8.27 | -7.44 | 9.50 | 61.53 | 5.42 |
| Core EBITDA Growth(%) | 1.19 | -0.11 | -4.07 | 59.14 | 19.44 |
| EBIT Growth(%) | 17.58 | 3.14 | -40.09 | 1,061.31 | 222.71 |
| PAT Growth(%) | 7.25 | -34.77 | -34.07 | 717.70 | 65.01 |
| EPS Growth(%) | 7.25 | -34.77 | -39.12 | 717.70 | 65.01 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.08 | 0.09 | 0.10 | 0.13 | 0.68 |
| Current Ratio(x) | 4.53 | 3.91 | 3.00 | 2.40 | 1.31 |
| Quick Ratio(x) | 2.99 | 2.46 | 1.64 | 1.17 | 0.68 |
| Interest Cover(x) | 477.45 | 322.44 | 76.69 | 4.73 | 0.40 |
| Total Debt/Mcap(x) | 0.09 | 0.20 | 0.12 | 0.15 | 7.94 |
Compare Financial Ratios of peers of VENUS REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| VENUS REMEDIES | ₹398.2 Cr | 0.9% | -7.7% | -19.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹422,271.0 Cr | -0.9% | -4.8% | 50.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹161,183.0 Cr | 3% | 5.9% | 65% | Stock Analytics | |
| CIPLA | ₹120,605.0 Cr | 1.5% | 0.1% | 19.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,869.0 Cr | -0.4% | -8.2% | 7.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,808.6 Cr | 0.6% | -5.3% | 51% | Stock Analytics | |
VENUS REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| VENUS REMEDIES | 0.9% |
-7.7% |
-19.9% |
| SENSEX | 3.5% |
-0.1% |
21.9% |
You may also like the below Video Courses
